The results reveal that the PI3K/AKT/mTOR pathway is aberrantly active in PCNSL and linked with a poor prognosis, which may foreshadow the development of novel therapeutic targets and prognostic variables [365]. This evidence concerns the gene MTOR and primary central nervous system lymphoma.